TAS 266

Drug Profile

TAS 266

Alternative Names: TAS-266

Latest Information Update: 15 Jan 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ablynx; Novartis
  • Developer Novartis
  • Class Antineoplastics
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Dec 2012 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 30 Sep 2012 Novartis terminates phase I trial in Solid tumours in the USA (NCT01529307)
  • 31 May 2012 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top